Article 107i Urgent Union Procedures: How Urgent Safety Action Works

Introduction

Most EU safety issues do not require an urgent Union procedure. They can be assessed through the ordinary pharmacovigilance system, including signal management, periodic reporting, post-authorisation measures, variations or, where necessary, one of the established referral procedures.

Article 107i of Directive 2001/83/EC addresses a different situation: a pharmacovigilance concern has reached a point at which urgent regulatory action is considered necessary.

The procedure is therefore not simply a faster version of an ordinary referral. It is a specific legal mechanism designed to coordinate urgent Union-level action when the potential regulatory consequences are sufficiently serious or immediate to require that mechanism.

The distinction matters for regulatory professionals because the phrase urgent safety issue is often used loosely. A safety concern can be serious without automatically becoming an Article 107i procedure. Conversely, an Article 107i procedure is not defined merely by the commercial or clinical importance of the issue. The legal conditions in the Directive determine when the procedure applies.

The central regulatory sequence is:

Pharmacovigilance concern
        ↓
Urgent regulatory action considered
        ↓
Member State / European Commission initiates procedure
        ↓
EMA + Member States + Commission informed
        ↓
PRAC assessment
        ↓
PRAC recommendation
        ↓
CHMP opinion or CMDh position/agreement
        ↓
Union / national implementation as applicable

The exact legal consequences depend on the circumstances and the authorisation route of the medicines concerned.

1. The Legal Basis: Article 107i

The urgent Union procedure is established in Section 4 of Chapter 3 of Title IX of Directive 2001/83/EC, beginning with Article 107i and followed by Articles 107j and 107k.

Article 107i provides the trigger for the procedure. It concerns situations arising from the evaluation of data from pharmacovigilance activities in which a Member State or the European Commission considers specified urgent regulatory action, or where certain other urgent safety actions are considered necessary for medicinal products authorised in more than one Member State.

The legal basis should therefore be read as a sequence rather than as a general statement that “urgent safety issues go to Article 107i”.

The starting question is:

Does the situation meet the statutory conditions for the urgent Union procedure?

Only after that question has been answered should the company or regulator reason about the operational pathway.

2. What Makes Article 107i Different?

The key feature is not simply speed. It is the combination of:

1. a concern arising from pharmacovigilance data;
2. a regulatory situation falling within the Article 107i framework; and
3. a need for urgent action or consideration of specified urgent regulatory measures.

Under Article 107i, the initiating authority may be a Member State or the European Commission, as appropriate. The marketing authorisation holder does not itself initiate the urgent Union procedure.

The procedure then brings the matter into a coordinated Union framework in which PRAC leads the scientific safety assessment.

This differs from an ordinary company-initiated regulatory change. The MAH may provide evidence, but it does not decide that the Union urgent procedure should exist or determine its scope.

3. When Is an Article 107i Procedure Initiated?

The Directive identifies several situations in which the urgent Union procedure can be triggered.

These include circumstances where, based on concerns resulting from the evaluation of pharmacovigilance data, a Member State or the Commission considers:

• suspending a marketing authorisation;
• revoking a marketing authorisation;
• prohibiting the supply of a medicinal product; or
• refusing renewal of a marketing authorisation.

The legal framework also covers certain situations involving urgent safety action such as a new contraindication, reduction in the recommended dose or restriction of indications for a medicinal product authorised in more than one Member State.

There are additional statutory circumstances connected with action taken or contemplated by the MAH because of safety concerns, including interruption of placing a product on the market or withdrawal of a marketing authorisation in the circumstances specified by the legislation.

These provisions should be read directly from the current consolidated Directive when assessing a live case. The practical EMA guidance explains the operation of the procedure, but the Directive remains the primary legal source.

4. Article 107i Is Not a General Emergency Button

A useful distinction is between clinical urgency and legal eligibility for the procedure.

A medicine can be associated with a potentially severe adverse reaction without automatically meeting the Article 107i conditions.

For example, a newly detected signal might be medically important but still require additional evaluation before urgent Union regulatory action is considered necessary.

Conversely, a rapidly emerging safety concern can create a situation in which the applicable legal criteria are met and immediate coordination is required.

The regulator therefore does not simply ask:

“Is this safety issue serious?”

It asks a more precise question:

“Given the pharmacovigilance evidence and the regulatory action being considered, does the situation fall within the statutory urgent Union procedure?”

This distinction prevents overuse of the procedure and avoids turning “urgent” into an imprecise synonym for “important”.

5. Who Can Initiate the Procedure?

The Article 107i procedure can be initiated by a Member State competent authority or the European Commission, as provided by the legislation.

An MAH cannot itself trigger the Article 107i procedure.

This does not mean that the MAH is passive.

An MAH has continuing pharmacovigilance obligations and must communicate relevant safety information to the competent authorities and EMA as required by EU legislation. Information from the MAH can therefore contribute materially to the evidence that leads a competent authority to consider urgent action.

But the legal act of initiating the urgent Union procedure belongs to the authority specified in Article 107i.

6. What Happens at Initiation?

The initiating authority informs the relevant EU actors and identifies the safety issue and regulatory action under consideration.

EMA's current practical guidance explains that the triggering notification is circulated to the Agency, Member States and the Commission. The notification identifies the safety concern and provides the scientific background and regulatory context.

Once the procedure is triggered, EMA publishes information about the procedure in accordance with its transparency arrangements. The procedure receives a dedicated regulatory record, including the relevant safety issue, products or active substances concerned, questions and timetable as applicable.

For the MAH, this creates an immediate operational requirement:

The company must move from routine safety management into controlled referral-response mode.

The first tasks are to establish the exact scope, identify the affected authorisations and understand the formal timetable and submission requirements.

7. Which Medicines Can Be Included?

Article 107i is particularly important because it can cover medicinal products with valid marketing authorisations in the European Economic Area, including products authorised nationally and products authorised through the mutual-recognition or decentralised procedures.

Where the safety issue concerns only centrally authorised medicinal products, the relevant pharmacovigilance referral mechanism under Article 20 of Regulation (EC) No 726/2004 is used instead.

The scope of an Article 107i procedure can therefore extend beyond a single MAH or product.

Depending on the safety issue, the procedure may concern:

• a specific medicinal product;
• several products containing the same active substance; or
• a broader group of products where the legal and scientific scope supports it.

An MAH does not choose whether its product is included. Inclusion follows the scope established for the procedure.

8. The Relationship With Article 20

Article 107i and Article 20 are easy to confuse because both are pharmacovigilance-driven Union procedures assessed scientifically by PRAC.

The authorisation status of the affected medicines is a critical distinction.

This table is deliberately simplified. The legal provisions should be consulted for the individual case.

The important point is that Article 107i is not simply the “urgent version” of Article 20.

9. PRAC Leads the Scientific Assessment

Once the urgent Union procedure is initiated, the Pharmacovigilance Risk Assessment Committee (PRAC) leads the scientific assessment.

At the beginning of the procedure, a PRAC rapporteur and co-rapporteur(s) are appointed to assess the evidence within the agreed procedural framework.

The assessment can involve data from:

• pharmacovigilance systems;
• individual case safety reports;
• clinical studies;
• epidemiological evidence;
• scientific literature;
• exposure information;
• previous regulatory assessments; and
• other relevant sources.

The scientific question is not simply whether an adverse event has occurred.

PRAC must assess what the available evidence means for the benefit-risk balance and appropriate regulatory action within the scope of the procedure.

10. The PRAC Assessment Is Urgent, Not Unstructured

Urgency does not remove the need for a structured scientific assessment.

PRAC rapporteurs assess the available evidence, consider information submitted by stakeholders and formulate a scientific conclusion for the committee.

The MAH is expected to provide relevant data within the published timetable.

EMA's current Article 107i guidance states that the time limit for stakeholder submissions should not exceed 20 days, while the PRAC recommendation normally has a maximum of 60 days after the submission deadline, with the possibility of a shorter timeframe where urgency is justified.

These are important procedural facts, but they should not be converted into a simplistic “20-day/60-day rule” detached from the individual procedure. The published procedure-specific timetable governs the live case.

EMA's procedural timetable is updated periodically; the current timetable should therefore be checked for the relevant referral.

11. The MAH's Immediate Responsibilities

Once the procedure starts, the MAH should establish a dedicated referral response structure.

The company should rapidly determine:

• which products and authorisations are in scope;
• which safety evidence is already available;
• what new analyses are required;
• who owns each scientific workstream;
• what questions must be answered;
• which regulatory documents must be submitted;
• who is the controlled EMA contact; and
• how the short timetable will be governed.

The MAH should not wait for the final PRAC recommendation before considering the consequences of possible regulatory outcomes.

However, contingency planning should remain clearly distinguished from the actual regulatory decision.

12. Why the QPPV Is Particularly Important

An Article 107i procedure can test the responsiveness and maturity of the pharmacovigilance system.

The QPPV should have oversight of the safety evidence supporting the company's response and should understand how the urgent concern relates to the existing pharmacovigilance system.

Relevant questions include:

• When was the signal first identified?
• How was it previously assessed?
• What new evidence changed the assessment?
• Are there unresolved discrepancies between the safety database and other evidence sources?
• Are additional cases or literature emerging during the procedure?
• Does the urgent issue affect the current RMP?
• Are existing risk-minimisation measures adequate?
• What immediate changes to PV monitoring may be required?

The QPPV does not replace the Regulatory Affairs function or the PRAC assessment.

The role is to maintain appropriate pharmacovigilance oversight and ensure that the company's safety position is consistent with the PV system.

13. The Difference Between Urgent Regulatory Action and Routine Signal Management

Routine signal management asks whether a new or changed signal warrants further evaluation and action within the pharmacovigilance system.

An Article 107i procedure addresses a different regulatory threshold: the circumstances have progressed to the point where urgent Union action is considered within the statutory framework.

This can be understood conceptually as:

New safety information
        ↓
Signal detection / validation
        ↓
Signal assessment
        ↓
Regulatory significance assessed
        ↓
Is urgent Union action legally indicated?
        ↓
             Yes
              ↓
         Article 107i

Not every signal reaches the bottom of this pathway.

The decision to use Article 107i belongs to the competent authority or Commission as provided by law, not to the QPPV or MAH alone.

14. Immediate National Action Can Still Occur

The existence of a Union procedure does not necessarily mean that Member States are powerless to act before the Union-level process concludes.

Under the Directive, where urgent action is necessary to protect public health, a Member State may suspend the marketing authorisation and prohibit the use of the medicinal product concerned on its territory pending a definitive decision, subject to the statutory notification requirements.

This is an important distinction:

The urgent Union procedure coordinates the Union-level assessment and outcome; it does not eliminate the Member States' ability to take immediate protective action where the legislation permits it.

For an MAH, this means that the company may need to manage both the immediate national consequences and the coordinated Union procedure.

15. What the Article 107i Procedure Is Trying to Achieve

The purpose is not simply to generate a PRAC recommendation quickly.

The broader regulatory objective is to allow the EU network to move rapidly from a serious pharmacovigilance concern to a coordinated assessment and, where justified, appropriate protective regulatory action.

This is particularly important where different Member States could otherwise take divergent actions in response to the same safety concern.

The procedure therefore combines:

• rapid information sharing;
• coordinated scientific assessment;
• participation of affected stakeholders;
• a Union-level recommendation or position; and
• subsequent implementation under the applicable legal framework.

Urgency and coordination are therefore inseparable features of the mechanism.

16. The MAH Submission: What Must Be Achieved

The MAH's submission in an Article 107i procedure has a difficult objective: it must be comprehensive enough to support a rapid scientific assessment without obscuring the decision-critical evidence.

The response should normally allow the assessors to understand:

• the nature and history of the safety concern;
• the relevant exposure to the medicinal product;
• the evidence supporting an association;
• evidence against or limiting that association;
• important uncertainties;
• the potential effect on the benefit-risk balance; and
• the regulatory measures the MAH considers appropriate.

The company should distinguish between evidence and interpretation.

For example, an increase in reports is an observation. Whether that increase represents a true increase in incidence, stimulated reporting, increased exposure, improved recognition or another phenomenon is an analytical question.

In an urgent procedure, the pressure to reach a conclusion quickly makes this distinction more important, not less.

17. Building the Evidence Package Under Time Pressure

An Article 107i timetable can require the MAH to mobilise evidence rapidly.

The response team should therefore establish an evidence inventory early.

A useful structure is:

The purpose of such an inventory is not to create a generic checklist for every procedure. It is to prevent important evidence from being overlooked when the available time is short.

18. New Evidence During an Urgent Procedure

The evidence base can continue to change while PRAC is assessing the issue.

New cases, literature, study results or other material information may become available after the initial submission.

The MAH should have a controlled process for identifying and evaluating such information and for determining whether it needs to be communicated through the procedure.

The company should be able to establish:

1. when the information became available;
2. what its potential regulatory significance was;
3. how it was medically and scientifically assessed;
4. whether it changed the benefit-risk interpretation; and
5. how it was handled within the applicable procedural framework.

Urgency does not justify withholding material information until the procedure has concluded.

At the same time, every new item should be assessed for relevance rather than automatically submitted without scientific evaluation.

19. Questions From PRAC and the Rapporteurs

PRAC may require clarification or additional information during its assessment.

The MAH should operate a question-management process that records:

• the exact question;
• the requested evidence;
• the scientific owner;
• the response deadline;
• the supporting analysis;
• review and approval; and
• the submitted response.

A question should be answered directly before additional contextual information is added.

Where the MAH disagrees with the premise of a question, it should explain the scientific basis for that disagreement rather than simply declining to answer.

The objective is to allow PRAC and its rapporteurs to assess the evidence efficiently.

20. Oral Explanations and Scientific Interaction

The urgent Union procedure provides for stakeholder participation within the applicable procedural framework, including the possibility of an oral explanation where the relevant procedure provides for it.

The MAH should treat any oral explanation as part of the formal scientific record.

The presentation should focus on the questions that remain genuinely material after the written evidence has been considered.

A useful structure is:

What the evidence establishes
        ↓
What remains uncertain
        ↓
How competing interpretations compare
        ↓
What regulatory action is proportionate

The purpose is not to turn an urgent procedure into an adversarial hearing.

The value of the interaction is that the committee can clarify the company's interpretation and test the assumptions underlying its proposed regulatory response.

21. PRAC Recommendation: The First Regulatory Conclusion

At the end of its assessment, PRAC adopts a recommendation within the applicable legal framework.

The recommendation reflects the committee's scientific assessment and the regulatory action it considers appropriate.

The MAH should read the recommendation carefully rather than reducing it to a headline such as “label change” or “restriction”.

The complete regulatory meaning may involve:

• the affected products;
• the scientific grounds;
• the benefit-risk conclusion;
• proposed conditions or restrictions;
• product-information changes;
• risk-management measures; and
• further pharmacovigilance requirements.

The exact content depends on the individual procedure.

Most importantly, a PRAC recommendation should not automatically be treated as the final legally operative Union decision.

22. What Happens After the PRAC Recommendation?

The downstream pathway depends on the medicines concerned and the legal framework governing the procedure.

Where centrally authorised medicines are concerned, the relevant Union process involves CHMP and subsequently the European Commission as applicable.

For nationally authorised medicines, the applicable pathway can involve the CMDh and subsequent implementation through the relevant national authorisations.

The regulatory professional should therefore ask three separate questions:

1. What has PRAC scientifically recommended?
2. What subsequent committee or coordination step is required?
3. What is the legally operative decision or position that the MAH must implement?

Collapsing these three stages into “EMA decided” can obscure the actual legal sequence.

23. Implementation of Urgent Safety Action

Once the legally operative outcome is established, the MAH must translate it into controlled implementation.

Depending on the outcome, implementation may involve:

• changes to the SmPC;
• changes to the Package Leaflet;
• changes to labelling;
• changes to the RMP;
• additional risk-minimisation measures;
• additional pharmacovigilance activities;
• national implementation activities; or
• suspension, withdrawal or other restrictions where legally applicable.

The implementation plan should be based on the final regulatory instrument rather than on an earlier PRAC draft or internal contingency scenario.

The company should also preserve evidence showing what changed, when it changed and how completion was verified.

24. Urgent Action Does Not End With Product Information

A common misconception is that once the warning or restriction has been incorporated into the SmPC and Package Leaflet, the urgent procedure is operationally complete.

That is often too narrow.

If the regulatory conclusion changes the understanding of a safety risk, the MAH should assess its consequences for the wider pharmacovigilance system.

Relevant areas can include:

• signal monitoring;
• case follow-up;
• medical review;
• aggregate safety reporting;
• RMP activities;
• effectiveness evaluation of risk-minimisation measures; and
• ongoing regulatory surveillance.

The label is one controlled output of the regulatory assessment. It is not necessarily the complete implementation of the safety conclusion.

25. Article 107i and the RMP

An urgent Union procedure can reveal that the existing risk-management strategy is no longer adequate or that additional information is required.

The MAH should therefore assess whether the regulatory outcome affects:

• important identified risks;
• important potential risks;
• missing information;
• routine risk-minimisation measures;
• additional risk-minimisation measures;
• additional pharmacovigilance activities; or
• the overall safety specification.

The precise RMP consequence depends on the final regulatory requirements.

An Article 107i procedure should not be treated as a separate event that disappears from the RMP once the urgent restriction has been implemented.

The regulatory conclusion becomes part of the continuing risk-management lifecycle.

26. Article 107i and the QPPV's Ongoing Oversight

The QPPV's role does not end when PRAC adopts its recommendation.

The QPPV should understand the regulatory conclusion sufficiently to assess whether the pharmacovigilance system has been appropriately adjusted.

Questions may include:

• Does the safety signal require continued enhanced monitoring?
• Does the signal assessment need to be updated?
• Are additional cases expected or particularly important?
• Does the RMP need revision?
• Are additional PV activities required?
• Have risk-minimisation measures changed?
• Does the new safety information affect aggregate-reporting strategy?
• Has the safety conclusion been incorporated consistently into relevant PV processes?

The QPPV should also maintain awareness of residual uncertainty.

An urgent regulatory action may reduce immediate risk while leaving important scientific questions unresolved. Those questions can become the focus of subsequent pharmacovigilance activities.

27. When Immediate Action Is More Important Than a Complete Evidence Picture

One of the hardest regulatory judgments in an urgent procedure is deciding what to do when evidence is incomplete.

A regulator does not necessarily need definitive causal proof before taking a protective regulatory measure.

The relevant decision depends on the evidence, the seriousness and plausibility of the risk, the affected population, the available benefits, alternatives and the consequences of action or inaction within the applicable legal framework.

This is not the same as lowering scientific standards.

It means recognising that regulatory decisions can be made under uncertainty when protection of public health requires action.

The MAH should therefore avoid framing the discussion as a binary choice between “proven risk” and “no action”.

The scientifically stronger approach is to describe the evidence and uncertainty and then explain what regulatory measure is proportionate to that evidence.

28. Common Misconceptions About Article 107i

“Article 107i means the medicine is being withdrawn.”

No. The procedure can lead to different regulatory outcomes depending on the evidence and applicable legal framework.

“Any serious safety signal should be Article 107i.”

No. The statutory conditions for the procedure must be satisfied.

“The MAH can initiate Article 107i.”

No. The legal initiation mechanism belongs to the authorities specified in Article 107i.

“PRAC makes the final legal decision.”

PRAC performs the scientific pharmacovigilance assessment and adopts its recommendation within the procedure. Subsequent legal decision-making depends on the applicable pathway.

“Urgent means there is no opportunity for the MAH to respond.”

No. The procedure includes stakeholder participation and submission arrangements, although the available time is constrained by the urgent nature of the process.

“Once the label changes, PV work is finished.”

No. The regulatory conclusion can affect the continuing PV and risk-management system.

“The urgent procedure removes the need for scientific uncertainty to be documented.”

The opposite is true. Understanding and communicating uncertainty is particularly important when decisions must be made rapidly.

29. Inspection Perspective

An Article 107i procedure can become an important inspection trail because it tests whether the pharmacovigilance system can respond to a rapidly developing safety concern.

An MAH should be able to reconstruct:

Safety information
      ↓
Signal / concern identified
      ↓
Assessment and escalation
      ↓
Urgent Union procedure
      ↓
MAH evidence and response
      ↓
PRAC assessment
      ↓
Regulatory outcome
      ↓
Implementation
      ↓
Ongoing monitoring

The exact inspection questions will depend on the circumstances, but the company should be able to demonstrate traceability between the original safety information, its internal assessment, the regulatory response and subsequent implementation.

The urgency of the procedure does not remove the need for a controlled record.

30. Article 107i in the Broader EU Safety Architecture

Article 107i makes most sense when viewed as one component of the broader EU pharmacovigilance system.

The conceptual progression is:

Routine pharmacovigilance
        ↓
Signal detection and assessment
        ↓
Regulatory evaluation
        ↓
Urgent action required?
        ↓
       Yes
        ↓
Article 107i / applicable urgent Union pathway
        ↓
PRAC scientific assessment
        ↓
Regulatory decision and implementation
        ↓
Continuing pharmacovigilance

The procedure is therefore neither a replacement for routine pharmacovigilance nor simply an accelerated variation.

It is a mechanism for moving an urgent safety concern into coordinated Union regulatory action while preserving a structured scientific assessment.

Key Takeaways

1. Article 107i is a specific urgent Union pharmacovigilance procedure established in Directive 2001/83/EC.
2. It is not simply a faster version of every other EU referral procedure.
3. The statutory conditions for initiating the procedure must be established before assuming that Article 107i applies.
4. A Member State competent authority or the European Commission can initiate the procedure as provided by law; the MAH does not initiate it.
5. PRAC leads the scientific pharmacovigilance assessment.
6. Urgency accelerates the process but does not eliminate structured scientific assessment or stakeholder participation.
7. The MAH must rapidly assemble evidence, respond to questions and maintain controlled governance of the submission.
8. The QPPV should maintain oversight of the pharmacovigilance evidence and the effect of the procedure on the PV system.
9. Immediate national protective action can coexist with the Union-level urgent procedure where the legislation permits it.
10. A PRAC recommendation is an important scientific regulatory conclusion but should not automatically be treated as the final legally operative decision.
11. The downstream pathway depends on the authorisation status and applicable legal framework.
12. Implementation can affect product information, the RMP, additional risk-minimisation measures and pharmacovigilance activities.
13. The urgent procedure does not end when the immediate safety action is implemented; continuing monitoring and risk management remain part of the lifecycle.
14. The quality of an urgent response depends not on eliminating uncertainty but on representing the evidence and uncertainty accurately enough to support proportionate regulatory action.

References

1. European Parliament and Council. Directive 2001/83/EC, as amended — Articles 107i–107k. Primary legal basis for the urgent Union procedure arising from pharmacovigilance data.
2. European Parliament and Council. Regulation (EC) No 726/2004, as amended. Primary legal framework for centrally authorised medicines and Article 20 pharmacovigilance procedures.
3. European Medicines Agency. Questions and answers: Urgent Union procedures (Article 107i). Current EMA procedure-specific guidance concerning initiation, submissions, PRAC assessment, stakeholder participation and implementation.
4. European Medicines Agency. Referral procedures for human medicines. Current overview of EU referral mechanisms and procedural information.
5. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Current information concerning PRAC's role and responsibilities.
6. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module IX — Signal Management. Current guidance on signal detection, validation, analysis and management.
7. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module V — Risk Management Systems. Current guidance concerning risk-management plans and risk-minimisation measures.
8. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module I — Pharmacovigilance systems and their quality systems. Current guidance relevant to pharmacovigilance governance and quality systems.
9. European Medicines Agency. Current procedural timetables for referrals. Procedure-specific timelines should be checked for the individual referral because EMA updates procedural material periodically.

Regulatory Note

This article is an educational explanation of the Article 107i urgent Union procedure. It is not legal advice and does not replace the current consolidated text of Directive 2001/83/EC, Regulation (EC) No 726/2004, EMA procedural guidance, GVP, national requirements or the formal documents governing an individual procedure.

The article deliberately distinguishes legal initiation, scientific assessment, committee recommendation or position, legally operative decision-making and implementation. These stages should not be collapsed into the informal statement that “EMA decided” an urgent safety action.

The exact trigger, scope, timetable, stakeholder participation, downstream decision-making and implementation requirements depend on the individual procedure and the applicable legal provisions.

The procedural timelines described in this article should be checked against the current EMA timetable and the formal documents for the individual procedure. Urgency does not create a universal fixed timetable beyond the requirements established by the applicable legal and procedural framework.

For an active Article 107i procedure, the current legislation, formal notification, procedure-specific timetable, EMA communications, PRAC documents and final legally operative regulatory instrument take precedence over this general educational explanation.